Video
Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma
Author(s):
In Partnership With:
Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.
Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.
The combination regimen has shown significant promise for patients, Postow explains. Phase I data showed that the regimen demonstrates a very high response rate in patients, while long-term follow-up results have shown impressive survival benefits. The combination has been tested against both nivolumab and ipilimumab as single agents.
Phase III data of the CheckMate-067 trial, presented at the 2015 ASCO Annual Meeting, includes progression-free survival and overall response rates. However, Postow is anticipating the overall survival data.
